EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Clinical and economic impact of pharmacist interventions to identify drug-related problems in multidisciplinary cancer care: a prospective trial

Jean-Stéphane Giraud, Virginie Korb-Savoldelli, Germain Perrin, Anne Jouinot, Brigitte Sabatier, Rui Batista, Matthieu Ribault, Sixtine De Percin, Clémentine Villeminey, Margaux Videau, Benoit Blanchet iD, Francois Goldwasser und 2 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyae213 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Jean-Stéphane Giraud und 13 weiteren Autor:innen. Beteiligte Einrichtung: Service Pharmacie, Assistance Publique - Hôpitaux Paris, Hôpital Cochin, F-75014 Paris, France. Hauptthemen laut MEDLINE: Pharmacists, Neoplasms, Antineoplastic Agents, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: French Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prescription of antitumor drugs has often been associated with drug-related problems. Pretherapeutic multidisciplinary risk assessment programs including pharmaceutical care have been established to secure the initiation of injectable and oral antitumor therapies. This prospective cross-sectional double-center study evaluated the clinical and economic impact of the pharmacist in detecting drug-related problems in patients initiating antitumor therapies. Materials and Methods Following pharmaceutical consultations, pharmaceutical interventions were validated by a multidisciplinary team. A committee of independent clinical experts assessed the potential clinical impact of drug-drug interactions. The association of clinical variables with pharmaceutical interventions was tested using a multivariate logistic regression model. Pharmacist cost of the program was assessed by valuing pharmacists’ time at their salaries and compared with potentially avoided costs.

Results

Four hundred thirty-eight patients with solid tumors were included: 62% males, mean age of 65 ± 13 years, and average of 6 medications. Half of the patients required at least one pharmaceutical intervention and independent factors associated with pharmaceutical interventions were the number of medications (5-9 vs <5: OR = 2.91 [95% CI 1.82-4.65], P < .001) and the type of antitumor treatment (immunotherapy vs intravenous chemotherapy: OR = 0.35 [95% CI 0.18-0.68], P = .002). One hundred seventy-four out of 266 pharmaceutical interventions (130 patients) involved clinically significant drug-drug interactions. Pharmacist costs were estimated to range between €4899 and €6125. Average costs were estimated at €11.4-14.3 per patient. Avoided hospitalization costs were estimated to be €180 633.

Conclusion

Clinical pharmacists contribute to the cost-effective reduction of drug-related problems in pre-therapeutic assessment programs for patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacistsNeoplasmsAntineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsHumansMaleFemaleAgedMiddle AgedProspective StudiesCross-Sectional StudiesDrug InteractionsPatient Care Team

Stichwörter der Autor:innen

antineoplastic agentsclinical pharmacistcost-benefit analysisdrug interactionsrisk assessment

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Service Pharmacie, Assistance Publique - Hôpitaux Paris, Hôpital Cochin, F-75014 Paris, France.
  • Service Pharmacie, Assistance Publique - Hôpitaux Paris, Hôpital européen Georges-Pompidou, F-75015 Paris, France.
  • Université Paris Saclay, Faculté de Pharmacie, Département de Pharmacie Clinique, Université Paris Saclay, 91400 Orsay, France.
  • HeKA, Inria Paris, Paris, France.
  • Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, INSERM, Paris, France.
  • Institut Cochin, Inserm, CNRS, Université Paris Cité, F-75014 Paris, France.

ORCID-Profile: Benoit Blanchet, Audrey Thomas-Schoemann

Förderung

  • French Ministry of Health

Zitieren

APA

Giraud, J. S., Korb-Savoldelli, V., Perrin, G., Jouinot, A., Sabatier, B., Batista, R., Ribault, M., De Percin, S., Villeminey, C., Videau, M., Blanchet, B., Goldwasser, F., Degrassat-Theas, A., & Thomas-Schoemann, A. (2025). Clinical and economic impact of pharmacist interventions to identify drug-related problems in multidisciplinary cancer care: a prospective trial. The Oncologist. https://doi.org/10.1093/oncolo/oyae213

Vancouver

Giraud JS, Korb-Savoldelli V, Perrin G, Jouinot A, Sabatier B, Batista R, et al. Clinical and economic impact of pharmacist interventions to identify drug-related problems in multidisciplinary cancer care: a prospective trial. The Oncologist. 2025. doi:10.1093/oncolo/oyae213

BibTeX
@article{Giraud2025,
  author = {Giraud, Jean-Stéphane and Korb-Savoldelli, Virginie and Perrin, Germain and Jouinot, Anne and Sabatier, Brigitte and Batista, Rui and Ribault, Matthieu and De Percin, Sixtine and Villeminey, Clémentine and Videau, Margaux and Blanchet, Benoit and Goldwasser, Francois and Degrassat-Theas, Albane and Thomas-Schoemann, Audrey},
  title = {Clinical and economic impact of pharmacist interventions to identify drug-related problems in multidisciplinary cancer care: a prospective trial},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyae213}
}
Kostenlos starten →